Latest News

  • INNOVATION

    25 Feb 2026

    Can AI Rethink How New Drugs Are Found?

  • PARTNERSHIPS

    24 Feb 2026

    Lilly Deepens AI Push in Obesity Drug Race

  • INVESTMENT

    23 Feb 2026

    Another Shot in the Obesity Gold Rush

  • MARKET TRENDS

    19 Feb 2026

    Precision Medicine Rises as Biomarkers Drive Change

Pfizer Steps Up Obesity Push With Metsera Deal

Pfizer corporate logo displayed outside office building

PARTNERSHIPS

17 Feb 2026

US drugmaker agrees multibillion-dollar acquisition to bolster metabolic pipeline and challenge leaders in weight-loss therapies

Gloved researcher examining pharmaceutical vial

REGULATORY

12 Feb 2026

FDA Tightens Grip on GLP-1 Copycats

FDA moves against copycat GLP-1 drugs, strengthening approved giants and reshaping the obesity market

Automated laboratory system screening drug compounds in petri dish

INNOVATION

11 Feb 2026

The New Front Line in AI Drug Discovery

Deep EigenMatics tops 2025 AI drug patents, speeding early discovery in obesity and diabetes research

AstraZeneca logo displayed on glass office building facade

PARTNERSHIPS

10 Feb 2026

AstraZeneca Bets on AI to Rethink Obesity Care

AstraZeneca and CSPC join forces, blending AI and long-acting dosing to speed new obesity and diabetes drugs across global markets

Close-up of GLP-1 text under magnifying glass with obesity and diabetes terms

MARKET TRENDS

5 Feb 2026

Patients Take the Lead in US Metabolic Drug Pricing

Patients, not just policymakers or drugmakers, are reshaping access and pricing in the fast-growing US metabolic therapy market

AstraZeneca logo on pharmaceutical company headquarters

PARTNERSHIPS

3 Feb 2026

AstraZeneca Brings AI In-House to Speed Drug Discovery

AstraZeneca acquires Modella AI to embed data and AI directly into research, signaling how central artificial intelligence has become to m...

Clinician reviewing laboratory data beside test tubes in medical research setting

RESEARCH

30 Jan 2026

New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

Early clinical data revive a sidelined liver pathway, drawing fresh attention while leaving Phase 2 results as the real test

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.